ArticleJournal of the American Heart Association2025
Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels and Long-Term Cardiovascular Outcomes in Survivors of Breast Cancer: A UK Biobank Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Cardiometabolic-to-Cancer Axis: Molecular Insights From Cardio-Kidney-Metabolic Syndrome Staging.JACC. CardioOncology · 2026Article
- PTSD and suPAR: A multicohort investigation of chronic inflammation.Brain, behavior, and immunity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBreast cancer is associated with increased risk for cardiovascular disease. suPAR (soluble urokinase plasminogen activator receptor) is an immune-derived signaling glycoprotein implicated in the pathogenesis of atherosclerosis, as well as cancer, representing a shared risk factor for these conditions. We sought to examine whether elevated proteomics-based suPAR levels are associated with cardiovascular death or incident coronary artery disease in survivors of breast cancer.
methodsWe leveraged Olink proteomics-based measurement of suPAR levels in 845 female survivors of breast cancer without cardiovascular disease enrolled in the UK Biobank. We examined the association between suPAR levels and the primary composite end point of cardiovascular death or incident coronary artery disease with Fine and Gray competing-risk regression, while accounting for the competing risk of noncardiovascular death and adjusted for clinical variables and C-reactive protein levels.
resultsThe median age was 61.0 years, and 96% were of White race. Over a median follow-up of 13.4 years, 84 (9.9%) events of cardiovascular death or incident coronary artery disease occurred. After adjustment for demographics, traditional cardiovascular risk factors, and C-reactive protein levels, proteomics-based suPAR levels (per 1 SD) were independently associated with adverse cardiovascular outcome risk (subdistribution hazard ratio [sHR], 1.48 [95% CI, 1.16-1.88],
conclusionsIn this cohort study of survivors of breast cancer, proteomics-based suPAR levels were associated with an increased risk for adverse cardiovascular outcomes, highlighting the potential role of suPAR as a shared risk factor for cancer and cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.